Click the title above for a link to open the Pharmaceutical Executive March 2024 issue in an interactive PDF format.
Pharmaceutical Executive: March 2024
The new season could bring with it more possibilities for renewal in the biotech sector, as our coverage this month highlights.
Paige Bingham has focused her career on improving clinical research operations and logistics, and not just ways to ease the burden for investigators and teams running the trials—but also for the patients involved in them.
A look at pharma and biotech financing, M&A, and stock market performance in 2023—and where developments may head next as company executives continue to navigate stormy but perhaps stabilizing waters in the months ahead.
Four steps to maximize the impact of medical information services as an engagement gateway.
Classic views on leadership are sometimes still the most effective.
The recent rally in the sector may have legs.
Planning for a post-recession scenario is essential, ensuring companies are prepared to scale up when funding permits.
Amid shifting healthcare cost strategies, how manufacturers can apply past lessons to best support patients and help boost drug adherence.
Dr. Chris Smyth, president of ICON Biotech, discusses emerging trends in the biotech space.
